OncoMatch/Clinical Trials/NCT06792162
PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Is NCT06792162 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Carilizumab and Apatinib for gastric cancer.
Treatment: Carilizumab and Apatinib — Evaluate the safety and efficacy of PD-1 antibody Carilizumab combined with apatinib for the conversion therapy of unresectable stage III and IV dMMR gastric cancer.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Cancer type
Gastric Cancer
Biomarker criteria
Required: MLH1 loss (complete loss of at least one protein)
complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6
Required: PMS2 loss (complete loss of at least one protein)
complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6
Required: MSH2 loss (complete loss of at least one protein)
complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6
Required: MSH6 loss (complete loss of at least one protein)
complete loss of at least one protein, MLH1, PMS2, MSH2, and MSH6
Disease stage
Required: Stage III, IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: surgery
Without surgery...for the gastric cancer lesion or metastatic tumor
Cannot have received: radiation therapy
Without...radiation therapy...for the gastric cancer lesion or metastatic tumor
Cannot have received: immunotherapy
Without...immunotherapy for the gastric cancer lesion or metastatic tumor
Cannot have received: traditional Chinese medicine, traditional Chinese patent medicines, simple preparations, immunomodulator (such as thymosin, interleukin, etc.)
Exception: must be ≥ 2 weeks since last use
The time from the end of traditional Chinese medicine, traditional Chinese patent medicines and simple preparations and immunomodulator (such as thymosin, interleukin, etc.) that have used anti-tumor drugs in the past to the start of the study must be ≥ 2 weeks
Lab requirements
Blood counts
no severe abnormalities in blood or bone marrow function
Kidney function
no severe abnormalities in kidney function
Liver function
no severe abnormalities in liver function
Cardiac function
no severe abnormalities in heart function
The main organ functions are normal, and there are no severe abnormalities in blood, heart, lung, liver, kidney, bone marrow, or immunodeficiency diseases.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06792162 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require MLH1?
Yes, MLH1 loss is a required biomarker for enrollment.
Does this trial require PMS2?
Yes, PMS2 loss is a required biomarker for enrollment.
Does this trial require MSH2?
Yes, MSH2 loss is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages